Raman process monitoring signal processing patents: who holds the ground and where it is still open
16.6% concentration at the top. The five leading assignees combined account for 123 of the 739 records in scope — a meaningful cluster, but not a lock on the field. Filings held at 22 in both 2017 and the partial-year 2026, with a peak of 64 in 2019. The 2021-to-2024 span, the last window with complete publication data, moved from 55 to 47 filings, a -15% change — a cooling in pace rather than a reversal, since 2025-onward figures are still understated by publication lag.
- 1CELL THERAPY CATAPULT4.7%
- 2REGENERON PHARMACEUTICALS INC4.2%
- 3AMGEN INC2.7%
- 4VP HOLDINGS LLC2.7%
- 5ZYOMED HLDG INC2.3%
See the full raman process monitoring signal processing analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who are the leading patent holders in Raman process monitoring signal processing?
The dataset ranks 100 companies by family count, with the leading assignee holding 35 records, fifth place at 17 and tenth place at 11. The top five combined account for 16.6% of all 739 records in scope, and the top ten for 25.7%, which means the field has a visible leader but no single dominant controller. Most of the remaining filings are spread across a long tail of organisations with only a few records each, so competitive analysis needs to look well beyond the top names.
Is patent filing in this area growing or slowing down?
Filings peaked at 64 in 2019 and by 2024, the most recent year with complete publication data, had settled at 47, down from 55 in 2021 — a -15% change over that span. This looks like a cooling in pace rather than an active decline, and because publication typically lags filing by around 18 months, the apparent flatness in 2025 and 2026 figures is partly an artifact of incomplete data rather than a real drop. Anyone assessing momentum should treat the last one to two years of any trend line as provisional.
Which technology areas within Raman signal processing are still open for new filings?
Optical elements and systems (G02B) appear in only 4.2% of the 739 records, and healthcare informatics (G16H) in just 2.8%, both far behind the near-universal G01N material-analysis base and the 33.6% G01J light-measurement share. That gap suggests narrower opportunities in portable optics for signal collection, informatics integration for diagnostic Raman output, and feature-selection methods tailored to enzyme or DNA assays, where claim density is currently thin relative to the core spectroscopy methods.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Raman Process Monitoring Signal Processing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.